Second Quarter Earnings Calls, In Brief
Executive Summary
As second quarter earnings announcement shift into high gear, companies announce changes to manufacturing, progress on their drug launch efforts and their intentions to ramp up business development efforts.
You may also be interested in...
Onyx Kyprolis Launch Strategy Includes Speedy Delivery, Premium Price
Onyx is pricing new myeloma drug carfilzomib at $9,950 per cycle, 65% higher than Takeda/Millennium’s pioneering proteasome inhibitor Velcade. Launch plans include financial assistance for providers, comprehensive patient assistance program and transition for expanded access patients to commercial drug.
Teva’s New CEO Levin Urges “Fiscal, Strategic Discipline,” Reduces 2012 Guidance
In a hastily scheduled, between-quarters update, Teva takes down its 2012 guidance issued only five months ago. New CEO Jeremy Levin promises a full strategic rendering by year end, announces long-time Teva exec Allan Oberman as new head of U.S. generics and establishment of a global compliance committee.
Warner Chilcott Mum On Potential Suitors
Warner Chilcott didn’t address the elephant in the room – a potential acquisition – during its first quarter earnings call.